New drug targets Hard-to-Treat cancers with PIK3CA mutation
NCT ID NCT07383506
First seen Feb 03, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This early-phase study tests an experimental drug called CGT6297 in adults with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The main goals are to check the drug's safety and find the best dose, while also seeing if it can shrink tumors. About 90 participants with certain cancers, including endometrial and breast cancer, will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Austin
Austin, Texas, 78758, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.